Thrombosis and Haemorrhagic Diseases Unit, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy.
Haemorrhagic and Thrombotic Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Blood Transfus. 2022 Sep;20(5):420-432. doi: 10.2450/2021.0119-21. Epub 2022 Jan 8.
Acquired platelet function disorders (PFD) are rare bleeding diseases that should be suspected in all patients with unexplained mucocutaneous bleedings of recent onset, with no previous history of haemorrhages, and with normal coagulation test and platelet count. Drug-induced platelet function bleeding disorders are the most frequent PFDs and can easily be identified on the basis of recent administration of platelet-inhibiting drugs. Apart from these, the most challenging acquired PFDs are those caused by autoimmune mechanisms. In fact, demonstration of autoantibodies inhibiting platelet function may be difficult in most non-specialised centres. Among autoimmune PFDs (aPFDs), acquired Glanzmann thrombasthenia (aGT), which is caused by autoantibodies that bind to platelet αIIbβ3 integrin, inhibiting its function, is the most frequent. aGT can be associated with underlying haematological malignancies or autoimmune diseases but can also be idiopathic. More rarely, other immune-mediated PFDs can occur, such as acquired delta storage pool disease (aδSPD). Treatment of aPFDs must rely on the control of acute and chronic bleedings, treatment of the underlying disease in secondary forms, and immunosuppressive treatment for autoantibody reduction or eradication. aPFDs may completely resolve upon treatment of any underlying disease that may be present. In primary aPFDs, and in the majority of secondary forms, treatment relies on immunosuppressive therapies.Here we present a systematic review of previously described immune-mediated aGT and aδSPD cases. Clinical and laboratory characteristics, treatments for the control of bleedings and for the eradication of autoantibodies, and responses to treatments are also discussed. Although no guidelines are available for the management of these very rare conditions, presentation of all cases reported so far can help clinicians in the diagnosis and treatment of these life-threatening diseases.
获得性血小板功能障碍(PFD)是罕见的出血性疾病,应怀疑所有近期出现不明原因黏膜出血、无既往出血史且凝血试验和血小板计数正常的患者。药物诱导的血小板功能障碍性出血性疾病是最常见的 PFD ,并且可以根据最近使用血小板抑制剂药物来轻易识别。除此之外,最具挑战性的获得性 PFD 是由自身免疫机制引起的。实际上,在大多数非专业中心,可能难以证明抑制血小板功能的自身抗体。在自身免疫性 PFD(aPFD)中,由结合血小板 αIIbβ3 整合素并抑制其功能的自身抗体引起的获得性 Glanzmann 血小板无力症(aGT)是最常见的。aGT 可与潜在的血液系统恶性肿瘤或自身免疫性疾病相关,但也可能是特发性的。更罕见的是,可能会发生其他免疫介导的 PFD,如获得性 δ 储存池病(aδSPD)。aPFD 的治疗必须依赖于控制急性和慢性出血、治疗继发性疾病的基础疾病以及减少或消除自身抗体的免疫抑制治疗。任何可能存在的基础疾病的治疗都可能使 aPFD 完全缓解。在原发性 aPFD 和大多数继发性形式中,治疗依赖于免疫抑制疗法。在此,我们对以前描述的免疫介导性 aGT 和 aδSPD 病例进行了系统回顾。还讨论了控制出血和消除自身抗体的治疗以及对治疗的反应的临床和实验室特征、治疗。尽管目前尚无这些非常罕见疾病的管理指南,但目前报告的所有病例的介绍可以帮助临床医生诊断和治疗这些危及生命的疾病。